Creative Medical Technology Holdings Inc

NASDAQ CELZ

Data sourced from iex and EODHD
Download Data

Creative Medical Technology Holdings Inc Non-Controlling Interest 3 year CAGR for the quarter ending June 30, 2023

Creative Medical Technology Holdings Inc Non-Controlling Interest 3 year CAGR is NA for the quarter ending June 30, 2023. Non-Controlling Interest represents the portion of a subsidiary's net income that is attributable to minority shareholders. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Creative Medical Technology Holdings Inc Non-Controlling Interest for the quarter ending March 31, 2023 was USD 50.20 K, a 0.00% change year over year.
  • Creative Medical Technology Holdings Inc Non-Controlling Interest for the quarter ending March 31, 2022 was USD 0.00, a 0.00% change year over year.
  • Creative Medical Technology Holdings Inc Non-Controlling Interest for the quarter ending March 31, 2021 was USD 0.00, a 0.00% change year over year.
  • Creative Medical Technology Holdings Inc Non-Controlling Interest for the quarter ending March 31, 2020 was USD 0.00, a 0.00% change year over year.
NASDAQ: CELZ

Creative Medical Technology Holdings Inc

CEO Mr. Timothy Warbington
IPO Date Nov. 6, 2015
Location United States
Headquarters 211 East Osborn Road, Phoenix, AZ, United States, 85012
Employees 4
Sector Healthcare
Industry Biotechnology
Description

Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

StockViz Staff

September 19, 2024

Any question? Send us an email